Dr. Steven Weisbord is an Associate Professor of Medicine and Clinical and Translational Science in the Renal-Electrolyte Division at the University of Pittsburgh and a Staff Nephrologist at the VA Pittsburgh Healthcare System. He is also an Associate Investigator at the Center for Health Equity Research and Promotion at the VA Pittsburgh Healthcare System. His main research interests include processes of care related to acute kidney injury and quality of life and symptom burden in maintenance hemodialysis patients. He is the Principal Investigator and Study Chairman of the ‘PRESERVE’ study, a VA Cooperative Studies Program sponsored multi-national, randomized clinical trial investigating interventions for the prevention of serious adverse outcomes related to contrast-induced acute kidney injury. The PRESERVE trial has enrolled over 4,000 patients and is the largest clinical trial of acute kidney injury ever conducted. His also co-Principal Investigator of a National Institutes of Health sponsored study that is ancillary to the PRESERVE trial and is establishing a biorepository of blood and urine samples of trial participants. This biobank will be used to identify blood and urine biomarkers for the stratification of risk for and diagnosis of the incipient stages of contrast-induced acute kidney injury. Dr. Weisbord also served as the Principal Investigator of the SMILE study, a multicenter clinical trial that compared two strategies for the management of symptoms in patients receiving chronic hemodialysis.